EB613 (oral PTH(1-34))

About Entera Bio

Entera Bio is a clinical-stage biotech focused on transforming injectable peptide therapies into convenient oral tablets using its proprietary N-Tab® drug delivery platform. The company's strategy de-risks development by targeting well-characterized peptides like PTH, with its lead asset, EB613 for osteoporosis, having completed a positive Phase 2 study and a streamlined Phase 3 protocol submitted in early 2026. Backed by a seasoned management team and strategic partnerships, Entera aims to redefine standards of care by improving patient adherence and enabling earlier therapeutic intervention.

Therapeutic Areas